Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength, which can place a considerable burden on healthcare systems. A significant unmet need exists for treatment that is safer, more-efficacious, and that will improve patient compliance. We discuss how current therapies are differentiated based on performance of key drug attributes, and measure the impact of these attributes on rheumatologists’ and endocrinologists’ prescribing behavior. We also discuss the most important unmet needs in the treatment of osteoporosis and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the trade-offs in key attributes, such as risk of fracture, safety, dosing burden, and price, that surveyed physicians are willing to make when considering new treatment options for osteoporosis.

Questions Answered

  • What are the treatment drivers and goals for osteoporosis?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for osteoporosis?
  • What are the prevailing areas of unmet need and opportunity in osteoporosis?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists and endocrinologists for a hypothetical new osteoporosis drug?

Product Description

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, and Germany.

Primary research: Survey of 60 U.S. and 30 European rheumatologists and endocrinologists fielded in January 2018.

Key companies: Amgen, Eli Lilly, Merck, Novartis, Pfizer, Radius Health, and UCB.

Key drugs: Evenity, Forteo, Prolia, and Tymlos.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Osteoporosis
      • Key Findings: Unmet Need in Osteoporosis and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the [[Indication]] Market and Emerging Therapy Insights
        • Opportunity: Therapies with Improved Safety Profiles and Dosing Regimens to Increase Compliance Rates
        • Opportunity: Availability of Additional Anabolic Agents
        • Opportunity: Drugs That Improve Bone Quantity and Turnover
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Osteoporosis Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): David Rees, Ph.D

David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.


Related Reports

Osteoporosis | Current Treatment | US | 2016

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with thes...

View Details

Osteoporosis | Current Treatment | Detailed, Expanded Analysis (US)

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with th...

View Details

Osteoporosis | Current Treatment | Detailed, Expanded Analysis Treatment Algorithms Claims Data Analysis (US)

A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, espe...

View Details

Osteoporosis | Landscape & Forecast | Disease Landscape & Forecast

Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The osteopo...

View Details